Slowly Progressive Type 1 Diabetes Mellitus: Current Knowledge And Future Perspectives

Area of Science:

• Endocrinology
• Immunology
• Pathology

Background:

• Slowly progressive type 1 insulin-dependent diabetes mellitus (SPIDDM), also known as latent autoimmune diabetes in adults (LADA), is often misdiagnosed.
• Lack of clear diagnostic criteria historically complicated SPIDDM management.
• The Japan Diabetes Society established clinical diagnostic criteria in 2012.

Purpose of the Study:

• To clarify the distinct pathological markers in the pancreas of SPIDDM patients.
• To review current understanding of SPIDDM pathogenesis, immunology, and epidemiology.
• To discuss diagnostic strategies, risk factors for beta-cell dysfunction, and treatment options.

Main Methods:

• Review of recent studies on pancreatic pathology in SPIDDM.
• Analysis of immunologic findings and diagnostic markers.
• Examination of epidemiological data and clinical features.

Main Results:

• SPIDDM pancreas shows T-cell-mediated insulitis and pseudoatrophic islets (beta-cell loss), characteristic of type 1 diabetes.
• Absence of amylin deposition, a marker for type 2 diabetes, is observed.
• Dipeptidyl peptidase-4 inhibitors show potential in preserving beta-cell function.

Conclusions:

• SPIDDM exhibits unique pathological features distinct from typical type 1 and type 2 diabetes.
• Early diagnosis is essential for preserving remaining beta-cell function.
• Further research into prevention and treatment strategies is warranted.